论文部分内容阅读
目的探讨利奈唑胺治疗恶性血液病患者合并革兰阳性菌感染的疗效与安全性。方法选择2009年3—8月福建省立医院血液科收治的临床诊断为合并革兰阳性细菌感染的恶性血液病患者18例,采用利奈唑胺600mg静脉滴注,每12h1次,直至临床感染症状缓解和影像学改善时停药。结果 18例患者中12例有明确感染灶,包括肺部8例,皮肤软组织3例,牙龈1例。所有患者中8例合并粒细胞缺乏,4例合并粒细胞低下。所有患者均在治疗14d后获得临床症状改善,其中8例肺部感染明显好转,3例皮肤感染痊愈。未发现明显的临床不良反应。结论利奈唑胺用于恶性血液病患者革兰阳性菌感染的治疗有较好临床疗效,且副反应小,安全性好。
Objective To investigate the efficacy and safety of linezolid in the treatment of patients with hematological malignancies complicated with Gram-positive bacterial infections. Methods 18 cases of malignant hematological diseases with Gram-positive bacterial infection admitted to Department of Hematology, Fujian Provincial Hospital from March to August in 2009 were enrolled. 18 cases were treated with linezolid 600mg intravenously every 12h until symptoms of clinical infection Mitigation and imaging discontinuation improved. Results Of the 18 patients, 12 had definite infection lesions, including 8 in the lungs, 3 in the skin and soft tissues, and 1 in the gums. Eight of the patients had neutropenia and four had low neutropenia. All patients received clinical symptoms improvement 14 days after treatment, of which 8 cases of pulmonary infection was significantly improved, and 3 cases of skin infections recovered. No obvious clinical adverse reaction was found. Conclusion Linezolid for the treatment of gram-positive bacterial infections in patients with hematologic malignancies has better clinical efficacy, and side effects of small, good safety.